atenolol has been researched along with Brain Ischemia in 6 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 7.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 3.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| "4 mg/kg by intraperitoneal injection Animals were dosed once every 2 hr for a total of five doses." | 1.28 | Nonlinear distribution of atenolol between plasma and cerebrospinal fluid. ( Fagan, SC; Gengo, FM; Hopkins, LN; Schuster, DP; Wagner, D, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saad, MA | 1 |
| Abbas, AM | 1 |
| Boshra, V | 1 |
| Elkhateeb, M | 1 |
| El Aal, IA | 1 |
| Gulliksen, G | 1 |
| Højer-Pedersen, E | 1 |
| Møller, M | 1 |
| Harvald, B | 1 |
| Enevoldsen, E | 1 |
| Davis, BR | 2 |
| Vogt, T | 1 |
| Frost, PH | 1 |
| Burlando, A | 1 |
| Cohen, J | 1 |
| Wilson, A | 1 |
| Brass, LM | 1 |
| Frishman, W | 1 |
| Price, T | 1 |
| Stamler, J | 2 |
| Perry, HM | 1 |
| Price, TR | 1 |
| Applegate, WB | 1 |
| Fields, WS | 1 |
| Guralnik, JM | 1 |
| Kuller, L | 1 |
| Pressel, S | 1 |
| Probstfield, JL | 1 |
| Bednar, MM | 1 |
| Gross, CE | 1 |
| Howard, DB | 1 |
| Russell, SR | 1 |
| Ellenberger, C | 1 |
| Gengo, FM | 1 |
| Fagan, SC | 1 |
| Hopkins, LN | 1 |
| Wagner, D | 1 |
| Schuster, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for atenolol and Brain Ischemia
| Article | Year |
|---|---|
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brain Ischemia; Cerebral Hemorrhage; Cerebr | 1998 |
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Brain Ischemia; Cerebral Hemorrhage; Chlorthalidone; Double | 2000 |
4 other studies available for atenolol and Brain Ischemia
| Article | Year |
|---|---|
Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor | 2010 |
Autoregulation of cerebral blood flow in patients with malignant hypertension and hypertensive encephalopathy.
Topics: Adult; Atenolol; Brain Diseases; Brain Ischemia; Cerebrovascular Circulation; Homeostasis; Humans; H | 1983 |
The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis.
Topics: Animals; Antihypertensive Agents; Aspirin; Atenolol; Brain Ischemia; Cerebrovascular Circulation; Dr | 2001 |
Nonlinear distribution of atenolol between plasma and cerebrospinal fluid.
Topics: Animals; Atenolol; Brain; Brain Ischemia; Humans; Rats | 1989 |